LPR is estimated to affect more than 20% of the United States population.
N-Zyme Biomedical seeks to provide much-needed treatments for the millions of people in the US and worldwide that suffer from LPR.
The disclosure provides a composition comprising of an inhaled and oral sustained-release formulation of an HIV protease inhibitor capable of inhibiting pepsin and a pharmaceutically acceptable carrier.Request Investor Presentation for details →
Founded by Franco Vigile, an enterpreneur, and Nikki Johnston, Ph.D., who dedicated her career to LPR research.Meet our team
N-Zyme is very pleased to announce that it’s Chief Scientific Officer, Dr. Nikki Johnston, and Chief Executive Officer, Franco Vigile, have filed a U.S. Patent Application: 63/392,929, Sustained-release oral fosamprenavir for the treatment of reflux on July 28, 2022.
The Medical College of Wisconsin received a "Study May Proceed" letter from The Center for Drug Evaluation and Research in the FDA approving their IND 149546 to assess the efficacy of fosamprenavir/Lexiva for the treatment of LPR in a phase Ill clinical trial. *An IND amendment request will be submitted for use of our sustained-release oral fosamprenavir formulation that is currently under development.
The Medical College of Wisconsin Institutional Review Board (IRB) has approved the 12-week randomized, double-blinded, placebo-controlled clinical trial to assess the efficacy of fosamprenavir/Lexiva for LPR, Protocol ID: PRO00037954.
International Patent Application: PCT/US2021/027758, Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux, was filed by the Medical College of Wisconsin on April 16, 2021. Nikki Johnston is the sole named inventor on that patent. Claims include use of HIV inhibitors for reflux (LPR, GERD, and airway reflux), by both local/inhaled and oral/systemic delivery.